Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabian Frontzek

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Blood|October 20, 2022
Tackling ALK-positive LBCLFabian Frontzek, Georg Lenz
Blood|January 20, 2022
CNS prophylaxis in DLBCL: time to say goodbye?Norbert Schmitz, Fabian Frontzek
Expert Review of Clinical Pharmacology|October 25, 2019
Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implicationsFabian Frontzek, Georg Lenz
Leukemia & Lymphoma|December 28, 2022
Plasmablastic lymphoma: from genetics to treatmentFabian Frontzek, Stephan Hailfinger, Georg Lenz
Therapeutic Advances in Hematology|July 5, 2022
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphomaFabian Frontzek, Imke Karsten, Norbert Schmitz, et al.
Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire|October 3, 2014
Functional interdependence of NHE1 and merlin in human melanoma cellsFabian Frontzek, Svenja Nitzlaff, Malte Horstmann, et al.
Cancer Cell International|November 16, 2019
MMP3 activity rather than cortical stiffness determines NHE1-dependent invasiveness of melanoma cellsDennis Keurhorst, Ivan Liashkovich, Fabian Frontzek, et al.
Leukemia|March 28, 2024
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trialMichael Oertel, Marita Ziepert, Fabian Frontzek, et al.
Leukemia|September 25, 2024
Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trialsGeorg Lenz, Hervé Tilly, Marita Ziepert, et al.
Leukemia|November 9, 2022
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphomaWendan Xu, Philipp Berning, Tabea Erdmann, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Blood|October 20, 2022
Tackling ALK-positive LBCLFabian Frontzek, Georg Lenz
Blood|January 20, 2022
CNS prophylaxis in DLBCL: time to say goodbye?Norbert Schmitz, Fabian Frontzek
Expert Review of Clinical Pharmacology|October 25, 2019
Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implicationsFabian Frontzek, Georg Lenz
Leukemia & Lymphoma|December 28, 2022
Plasmablastic lymphoma: from genetics to treatmentFabian Frontzek, Stephan Hailfinger, Georg Lenz
Therapeutic Advances in Hematology|July 5, 2022
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphomaFabian Frontzek, Imke Karsten, Norbert Schmitz, et al.
Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire|October 3, 2014
Functional interdependence of NHE1 and merlin in human melanoma cellsFabian Frontzek, Svenja Nitzlaff, Malte Horstmann, et al.
Cancer Cell International|November 16, 2019
MMP3 activity rather than cortical stiffness determines NHE1-dependent invasiveness of melanoma cellsDennis Keurhorst, Ivan Liashkovich, Fabian Frontzek, et al.
Leukemia|March 28, 2024
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trialMichael Oertel, Marita Ziepert, Fabian Frontzek, et al.
Leukemia|September 25, 2024
Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trialsGeorg Lenz, Hervé Tilly, Marita Ziepert, et al.
Leukemia|November 9, 2022
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphomaWendan Xu, Philipp Berning, Tabea Erdmann, et al.
Pageof 2